Inspira Technologies shares jump 15.63% intraday after completing UAE regulatory submission for ART100, advancing Gulf expansion plans.

Inspira Technologies surged 15.63% intraday after announcing the completion of regulatory submission for its FDA-cleared ART100 system to the UAE Ministry of Health and Prevention, with final approval expected imminently. The milestone, following high-level UAE government discussions, positions the company for potential nationwide deployment and commercial entry into the Gulf region. CEO Dagi Ben-Noon emphasized the UAE’s efficient regulatory framework and the team’s readiness to scale operations post-approval, reinforcing investor confidence in the company’s global expansion strategy. The news aligns with the stock’s sharp intraday gain, driven by optimism over accelerated market access in a fast-growing healthcare market.